Using molecular biology to develop drugs for renal cell carcinoma

Expert Opinion on Drug Discovery

Volumn 3, Issue 3, 2008, Pages 311-327

  Cowey, C Lance ^a   Rathmell, W Kimryn ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Hypoxia inducible factor; Renal cell carcinoma; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA2A INTERFERON; AMG 386; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CEDIRANIB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INFLIXIMAB; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VOLOCIXIMAB; ZK 225584;

ANEMIA; ANGIOGENESIS; ARTHRALGIA; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPHONIA; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEMATURIA; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOXIA; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAXIMUM TOLERATED DOSE; MOLECULAR BIOLOGY; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PAIN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 41149091197     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.3.311     Document Type: Review

References (103)

1. Pies LAG, Melbert D, Krapcho M, et al. (Eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, MD. Based on November 2006 SEER data submission, posted to the SEER web site, 2007. Available at: http://seer.cancer.gov/csr/1975_2004/
2. Wallen EM, Pruthi RS, Joyce GF, et al. Kidney cancer. J Urol 2007;177(6):2006-18; discussion 18-9
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163(2):408-17
4. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001;19(2):148-54
5. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530-40
6. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361(9374):2059-67
7. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260(5112):1317-20
8. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90
9. Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54(11):2852-5
10. Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002;34(1):58-68
11. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91(21):9700-4
12. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996;93(20):10589-94
13. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93(20):10595-9
14. Iwai K, Yamanaka K, Kamura T, et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999;96(22):12436-41
15. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995;269(5229):1444-6
16. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-5
17. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275(33):25733-41
18. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292(5516):464-8
19. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292(5516):468-72
20. Wiesener MS, Munchenhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61(13):5215-22
21. Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277(41):38205-11
22. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60(6):1541-5
23. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22(20):7004-14
24. Brugarolas JB, Vazquez F, Reddy A, et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4(2):147-58
25. Richard DE, Berra E, Gothie E, et al. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999;274(46):32631-7
26. Sang N, Stiehl DP, Bohensky J, et al. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278(16):14013-9
27. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997;57(23):5328-35
28. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1(3):E83
29. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
30. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
31. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
32. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178(5):1883-7
33. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
34. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
35. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11(15):5472-80
36. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16(10):1688-94
37. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855-61
38. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12
39. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
40. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;30(3):220-7
41. Amato RJ, Harris P, Dalton M, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5026
42. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
43. Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5032
44. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol (Meeting Abstracts) 2005;23(16S):4509
45. George D, Michaelson D, Oh WK, et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2003;22:1548
46. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
47. Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol (Meeting Abstracts) 2005;23(16 Suppl):3012
48. Suttle AB, Hurwitz H, Dowlati A, et al. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J Clin Oncol (Meeting Abstracts) 2004;22(14 Suppl):3054
49. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a Phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5031
50. Stopeck A, Sheldon M, Vahedian M, et al. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002;8(9):2798-805
51. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003;9(5):1648-55
52. Lara PN Jr, Quinn DI, Margolin K, et al. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003;9(13):4772-81
53. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25(21):3045-54
54. van Herpen C, Drevs J, van Cruijsen H, et al. Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): combined results from two phase I studies. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):3560
55. Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II Consortium. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5093
56. Dawson NA, Guo C, Zak R, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 2004;10(23):7812-9
57. Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21(3):341-5
58. Beeram M, Rowinsky EK, Weiss GR, et al. Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: a phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging. J Clin Oncol (Meeting Abstracts) 2004;22(14 Suppl):3050
59. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23(31):7889-96
60. Bukowski RM, Kabbinavar F, Figlin RA, et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):4523
61. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
62. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):3
63. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B 90206. A randomized Phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10(8):2584-6
64. Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2005;23(16 Suppl):3029
65. Rosen LS, Hong D, Chap L, et al. First-in-human study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in adult patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):3522
66. Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from phase II study of volociximab, an {alpha}5{beta}1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5094
67. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90(5):985-90
68. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006;175(1):57-62
69. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006;25(3):409-16
70. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor {alpha} as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25(29):4542-9
71. Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13(2 Pt 2):758s-763s
72. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18
73. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
74. Porter LL, Burris HA, Jones SF, et al. Summary of results in patients with metastatic renal cell cancer (RCC) from Phase I studies of RAD001 (everolimus). J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):14599
75. Jac J, Giessinger S, Khan M, et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5107
76. Chang H, Shyu KG, Lee CC, et al. GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem Biophys Res Commun 2003;302(1):95-100
77. Fossella FV MT, Wester M, Gorelick K, et al. Phase I trial of GL331, a novel topoisomerase-II inhibitor, for advanced refractory cancer. J Clin Oncol (Meeting Abstracts) 1996:1571
78. Liu JC, Chao L, Wu Y, et al. Phase II and Pharmacokinetic Study of Gl331 in Refractory Gastric Cancer Patients. J Clin Oncol (Meeting Abstracts) 2000:1202
79. Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002;277(33):29936-44
80. Liu YV, Baek JH, Zhang H, et al. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF- 1alpha. Mol Cell 2007;25(2):207-17
81. Ronnen EA, Kondagunta GV, Ishill N, et al. A Phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24(6):543-6
82. Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs 2006;15(6):709-19
83. Han JY, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005;97(17):1272-86
84. Kim SH, Jeong JW, Park JA, et al. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 2007;17(3):647-51
85. Fath DM, Kong X, Liang D, et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem 2006;281(19):13612-9
86. Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12(10):1247-52
87. Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3(3):233-44
88. Kirkpatrick L, Dragovich T, Ramanathan R, et al. Results from Phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies. J Clin Oncol (Meeting Abstracts) 2004;22(14 Suppl):3089
89. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004;6(1):33-43
90. Sutphin PD, Chan DA, Li JM, et al. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 2007;67(12):5896-905
91. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005;65(19):9047-55
92. Vlaminck B, Toffoli S, Ghislain B, et al. Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS J 2007;274(21):5533-42
93. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3(4):363-75
94. Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61(8):947-54
95. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95(7):516-25
96. George DJ, Michaelson MD, Rosenberg JE, et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5035
97. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5038
98. Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5099
99. Patel PH, Kondagunta GV, Redman BG, et al. Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5097
100. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25(22):3288-95
101. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25(22):3296-301
102. Speca JC, Mears AL, Creel PA, et al. Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5039
103. Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5034